Trials / Unknown
UnknownNCT04605627
The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Define a signature of gut microbiota composition and related metabolites in patients with ST-elevation myocardial infarction, non ST-elevation myocardial infarction and chronic coronary disease (CAD).
Detailed description
A total of 200 patients, allocated to 50 patients with chronic coronary syndrome, 75 patients with non-ST elevation myocardial infarction and 75 patients with ST- elevation myocardial infarction will be included. Clinical information, blood samples and fecal samples will be collected. Fecal and blood samples will be collected once in patients With chronic disease and in patients with acute coronary syndrome; in the acute phase and after 3 months.
Conditions
Timeline
- Start date
- 2020-10-08
- Primary completion
- 2021-12-31
- Completion
- 2023-12-31
- First posted
- 2020-10-28
- Last updated
- 2020-10-28
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT04605627. Inclusion in this directory is not an endorsement.